Personalis Inc Stock

$6.58

3.30% yesterday

Nasdaq, Jun 27, 10:12 pm CET

ISIN

US71535D1063

Symbol

PSNL

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Biotechnology

Overview Dividends Analysts Charts News Strategies

Personalis Inc Stock price

$6.58

-6.14 48.27% 5Y

Nasdaq, Closing price Fri, Jun 27 2025

+0.21 3.30%

ISIN

US71535D1063

Symbol

PSNL

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Biotechnology

Key metrics

Basic

Market capitalization

$581.2m

Enterprise Value

$399.1m

Net debt

$-182.1m

Cash

$185.7m

Shares outstanding

88.3m

Valuation (TTM | estimate)

P/E

negative | negative

P/S

6.78 | 6.84

EV/Sales

4.66 | 4.70

EV/FCF

negative

P/B

2.80

Financial Health

Equity Ratio

75.09%

Return on Equity

-40.05%

ROCE

-27.56%

ROIC

-91.61%

Debt/Equity

0.02

Financials (TTM | estimate)

Revenue

$85.7m | $85.0m

EBITDA

$-56.4m | $-81.9m

EBIT

$-67.1m

Net Income

$-84.1m | $-85.2m

Free Cash Flow

$-46.7m

Growth (TTM | estimate)

Revenue

15.56% | 0.45%

EBITDA

27.59% | -42.90%

EBIT

24.82%

Net Income

9.22% | -4.87%

Free Cash Flow

31.47%

Margin (TTM | estimate)

Gross

33.30%

EBITDA

-65.81% | -96.39%

EBIT

-78.28%

Net

-98.10% | -100.30%

Free Cash Flow

-54.51%

EPS

$-0.96

FCF per Share

$-0.53

Short interest

6.33%

Employees

229.00

Rev per Employee

$370.00k

As a Free StocksGuide user, you can view scores for all 6,914 stocks worldwide.

Get Started for Free Today

Personalis Inc Stock Analysis

Unlock Scores for Free

??

14 Analysts have issued a Personalis Inc forecast:

12x Buy

86%

More details on Analyst Estimates Including Price Targets

14 Analysts have issued a Personalis Inc forecast:

Buy

86%

Hold

14%

Analyst Estimates with Stock Price Targets

Financial data from Personalis Inc

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Mar '25		+/- %
Revenue	86 86	16% 16% 100%
- Direct Costs	57 57	4% 4% 67%
Gross Profit	29 29	50% 50% 33%
- Selling and Administrative Expenses	47 47	1% 1% 55%
- Research and Development Expense	49 49	20% 20% 57%
EBITDA	-56 -56	28% 28% -66%
- Depreciation and Amortization	11 11	6% 6% 12%
EBIT (Operating Income) EBIT	-67 -67	25% 25% -78%
Net Profit	-84 -84	9% 9% -98%

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

Personalis Inc Stock News

Neutral

Business Wire

●

25 days ago

Personalis' NeXT Personal® Predicts Cervical Cancer Recurrence Risk in New CALLA Phase 3 Study Analysis Presented at ASCO

FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced the presentation of new results from the CALLA phase 3 study showing for the first time its ultrasensitive NeXT Personal circulating tumor DNA (ctDNA) blood test detected cervical cancer progression, up to 16 months ahead of imaging. The results demonstrate the pote...

Neutral

Business Wire

●

26 days ago

New Data Shows NeXT Personal® Identifies Breast Cancer Patients Receiving Neoadjuvant Therapy that are at High Risk for Relapse

FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced the presentation of new clinical results from the PREDICT DNA and SCANDARE studies highlighting the capabilities of its ultrasensitive NeXT Personal circulating tumor DNA (ctDNA) blood test for monitoring and predicting neoadjuvant therapy (NAT) response in triple n...

Neutral

Business Wire

●

about one month ago

Personalis and Academic Partners to Present Latest Data on Ultrasensitive ctDNA Assay for Residual Cancer and Recurrence Detection

FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced multiple presentations at the American Society of Clinical Oncology (ASCO) Annual Meeting next week in Chicago, Illinois. The presentations feature new data from clinical studies utilizing the NeXT Personal® ultrasensitive ctDNA assay for residual and recurrent canc...

More Personalis Inc News

Company Profile

Personalis, Inc. engages in the provision of genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. The company was founded by Euan A. Ashley, Michael Snyder, Atul J. Butte, John S. West, and Russ B. Altman in 2011 and is headquartered in Menlo Park, CA.

Head office	United States
CEO	Christopher Hall
Employees	229
Founded	2011
Website	www.personalis.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now